ZGZvi Gur

Zvi Gur

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zvi Gur has a total of 26 co-authors. Here are the top co-authors by number of shared publications:

  • Itay Lavy

    Department of Ophthalmology, Hadassah University Medical Center, Faculty of Medicine, the Hebrew University of Jerusalem, Jerusalem, Israel

    2 shared publications
  • Itay Nitzan

    Department of Military Medicine and "Tzameret", Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel; Department of Ophthalmology, Hadassah-Hebrew University Medical Centre, Jerusalem, Israel

    2 shared publications
  • Michael Tabi

    Department of Ophthalmology, Hadassah University Medical Center, Faculty of Medicine, the Hebrew University of Jerusalem, Jerusalem, Israel

    2 shared publications
  • Nadav Shemesh

    Department of Ophthalmology, Hadassah University Medical Center, Faculty of Medicine, the Hebrew University of Jerusalem, Jerusalem, Israel

    2 shared publications
  • Nir Erdinest

    Departments of Ophthalmology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel

    2 shared publications
  • Tehila Shlomov

    Department of Ophthalmology, Hadassah–Hebrew University Medical Center

    2 shared publications

Latest Publications

  • Open Access

    Mentorship as metadata: clinical annotation and the limits of real-world data in oculoplastic surgery

    by Itay Nitzan, Tehila Shlomov, Zvi Gur

    In oculoplastic surgery, real-world databases capture diagnosis and procedure codes but rarely the clinical variables that define surgical meaning: laterality, levator function, margin-reflex distance, inflammatory activity, operative intent, or the reason for revision. We propose that clinical supervision be recorded as documented clinical interpretive annotation : an explicit, written layer that defines the limits of routinely collected data before they are analyzed. “Mentorship as metadata” names the educational relationship that produces this annotation and is used throughout as a labelled metaphor, not as a claim of equivalence with formal metadata, data provenance, or research-governance documentation. Synthesizing established reporting and causal-inference frameworks with recently published oculoplastic database studies (2019–2026), we develop a three-layer model: code, phenotype, and judgment, together with a pre-analysis phenotype map that trainees and mentors can complete before a query is run. Central to this framework is the “refusal point”: a documented, pre-specified boundary at which a dataset should not be used to answer a given clinical question, co-signed by the oculoplastic mentor, the trainee or lead analyst, and a methodologist and recorded as a routine study-design deliverable. The refusal point complements the estimand and target-trial frameworks by naming the adjacent, more tempting question that the data cannot answer. It introduces no new statistical construct; its contribution is documentary, procedural, and educational, and we state explicitly what each existing framework already requires and what remains unspecified. We advance one falsifiable hypothesis: that pre-specified, co-signed refusal-point documentation increases pre-analysis reframing of research questions and improves concordance between the protocol estimand and the estimand the published conclusions can support, and we set out a prospective programme capable of refuting it. Real-world data remain valuable for utilization, trends, and rare associations, but they are not self-interpreting. Training oculoplastic surgeon-scientists to name, in writing and before analysis, the boundary between code and clinical reality may make database research more transparent, restrained, and reproducible. In oculoplastics, mentorship is the clinical annotation that turns data into evidence.

    • 28 January 2026

    Association between semaglutide use and thyroid eye disease-related outcomes in autoimmune thyroiditis with type II diabetes.

    by Tehila Shlomov, Itay Nitzan, Rena Pollack, Ofira Zloto, Zvi Gur

    To evaluate whether semaglutide use is associated with thyroid eye disease (TED)-related outcomes among patients with autoimmune thyroiditis and type II diabetes mellitus (T2DM). Adults with thyrotoxicosis (International Classification of Diseases [ICD-10]: E05) and T2DM were identified from the TriNetX US Collaborative Network. T2DM was defined by ICD-10 (E11) or laboratory criteria. The exposed cohort included individuals prescribed semaglutide on or after its Foood and Drug Administration approval (December 5, 2017). The control cohort included patients treated with non-glucogon-like peptide-1 receptor agonist antihyperglycemic agents without prior glucagon-like peptide-1 receptor agonist exposure. Propensity score matching (1:1) was performed using demographics, comorbidities, medications, and health care utilization variables. Five-year outcomes included: (1) TED-related diagnoses; (2) systemic corticosteroid use; (3) TED-related surgical interventions; (4) radiation treatment; and (5) teprotumumab use. Risk ratios (RRs) with 95% confidence intervals (CIs) were calculated. After matching, 23,279 patients were included per group (mean age: 60.1 years; 75% female). At 5-year, semaglutide users had lower rates of TED-related diagnoses (2.16% vs 2.82%; RR: 0.76; 95% CI: 0.68-0.86), systemic corticosteroid use (22.71% vs 26.39%; RR: 0.86; 95% CI: 0.82-0.90), TED-related surgical interventions (0.30% vs 0.42%; RR: 0.70; 95% CI: 0.51-0.96), and radiation treatment (1.17% vs 2.05%; RR: 0.57; 95% CI: 0.49-0.67). Teprotumumab use was rare and similar between groups (0.08% vs 0.08%; RR: 1.00; 95% CI: 0.52-1.92). Semaglutide use was associated with fewer TED-related diagnoses and treatments over 5 years, supporting a potential protective role. Further studies are warranted to confirm these associations and clarify underlying mechanisms.

  • Open Access

    Evaluating a novel triangular suture technique for scleral support of dislocated intraocular lenses following cataract surgery: A retrospective cohort study

    by Nir Erdinest, Michael Tabi, Or Shmueli, Yossi Eshel, Salome Goldmann, Shoham Kubovsky, Aseel Gebara, Samer Khateb, Ori Saban, Edward Averbukh, et al.

    This study evaluates the safety and efficacy of a novel triangular suture technique (TST) as an alternative method to scleral-fixated intraocular lens implantation in patients with intraocular lens (IOL) dislocation following cataract surgery. The aim is to assess visual outcomes, intraocular pressure (IOP) control, and complication rates over an extended follow-up period. A retrospective cohort study analyzed 43 patients (48.8% female; mean age 77.9 ± 10.3 years) who underwent scleral-supported IOL implantation using the TST. Preoperative assessments included ocular history, baseline visual acuity, and IOP. Postoperative follow-up was conducted at 6 defined intervals over 26 months. All surgeries were performed using a uniform triangular scleral suture approach with 10-0 polypropylene in a three-point support pattern. Sutures were placed 3.0 mm posterior to the limbus at 11, 7, and 3 o’clock positions (corresponding to the triangular configuration), with subconjunctival passage between designated clock-hour positions to prevent erosion and ensure proper IOL centration. Outcome measures included uncorrected visual acuity, best-corrected visual acuity, IOP, glaucoma medication requirements, and central macular thickness. Uncorrected visual acuity improved significantly from 0.92 ± 0.55 to 0.50 ± 0.40 logarithm of the minimum angle of resolution (logMAR) at 6 months ( P < .01). Best-corrected visual acuity improved significantly from 0.75 ± 0.34 to 0.36 ± 0.42 logMAR at 6 months ( P < .01) and was maintained at 0.37 ± 0.50 logMAR at 26 months ( P < .01). A transient IOP rise was observed on the first postoperative day (mean 18.14 ± 5.65 mm Hg; P < .05), with normalization thereafter. No significant complications were observed over the 24-month follow-up period. The TST provides a safe and effective alternative to conventional scleral-fixated intraocular lens fixation methods, offering significant and sustained visual improvement, minimal complications, excellent IOL stability, and stable anatomical outcomes over extended follow-up.

  • Open Access

    Clinical Evaluation of Ripasudil for Corneal Edema: A Large-Scale Retrospective Cohort Study

    by Nir Erdinest, Michael Tabi, Nadav Shemesh, Jamel Corredores, Claudia Yahalom, Yossi Eshel, Benjamin Stern, David Smadja, Zvi Gur, Itay Lavy

    Objectives: This study evaluated the therapeutic potential of topical Ripasudil hydrochloride hydrate in managing various forms of corneal edema. Methods: This retrospective study included 96 patients of 72.20 ± 10.52 years, with 53 females (55.2%) who were treated with Ripasudil for corneal edema, with a mean treatment duration of 5.2 ± 2.3 months, divided into four groups: post-cataract surgery (n = 32), Fuchs endothelial corneal dystrophy (FECD; n = 29), post-Descemet membrane endothelial keratoplasty (DMEK; n = 25), and post-penetrating keratoplasty (PKP; n = 10). All patients were treated with Ripasudil, typically administered three times daily in the first week and twice daily in the following months. Clinical efficacy outcomes were assessed using changes in best-corrected visual acuity (BCVA), central corneal thickness (CCT), and endothelial cell count (ECC) with specular microscopy, anterior segment optical coherence tomography (OCT), and slit-lamp examination, while intraocular pressure (IOP) was measured using the iCare tonometer. Results: Ripasudil treatment led to a reduction in CCT and improvement in visual acuity across most groups, with minimal changes in ECC. CCT decreased by 30.44 μm (p < 0.001), 25.56 μm (p < 0.001), 8.41 μm (p = 0.05), and 6.80 μm (p > 0.1); visual acuity improved by 0.27 (p = 0.001), 0.18 (p = 0.02), 0.17 (p = 0.025), and 0.07 logMAR units (p > 0.1); and ECC changed by +7.0 (p > 0.1), 15.4 (p > 0.1), −7.6 (p > 0.1), and 2.3 cells/mm2 (p > 0.1) in the post-cataract surgery, FECD, post-DMEK, and post-PKP groups, respectively. Conclusions: No adverse events or progression of edema were recorded during the follow-up period. These findings support the role of Ripasudil as a non-invasive pharmacological approach to managing corneal edema and delaying or possibly avoiding surgical interventions, such as corneal transplantation, in selected cases.


  • Orbital nodular fasciitis in the pediatric population: a case report and review of the literature

    by Ana Navarrete, Arie Maya, Stephanie Benshushan, Shay Ofir, Yael Deckel, Zvi Gur

    A 10-month-old female presented with a rapidly growing, painless mass in the right upper eyelid. Due to suspected malignancy, she underwent an urgent biopsy. Histopathological and immunohistochemical analyses revealed nodular fasciitis. Here, we describe the case and perform a literature review of orbital nodular fasciitis in the pediatric population.